

## Special Issue

# Urologic Oncology: Biomarkers and Targeted Therapies

### Message from the Guest Editor

Urological malignancies, including prostate, urothelial, renal, and testicular cancers, pose significant challenges to patients due to their heterogeneity and variable responses to treatment. While traditional approaches can lead to suboptimal outcomes and unnecessary toxicity, new targeted therapies may represent a paradigm shift, offering personalised strategies tailored to the unique molecular profiles of tumors and patients. This Special Issue aims to bring together the latest advances in the discovery, validation, and clinical application of prognostic approaches and monitoring biomarkers for uro-oncology targeted therapies. From genomic and proteomic signatures (taking advantage of recent advances in machine learning and artificial intelligence) to circulating tumor cells and imaging biomarkers, each contribution will provide new insights into treatment response prediction, prognosis estimation, and therapy resistance mechanisms.

### Guest Editor

Dr. Razvan Bardan

1. Department of Urology, Victor Babes University of Medicine and Pharmacy, 300041 Timișoara, Romania
2. Department of Urology, Clinical Emergency County Hospital, 300723 Timișoara, Romania

### Deadline for manuscript submissions

closed (31 October 2024)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/200039](https://mdpi.com/si/200039)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).